Neuroscience News and Research

RSS

RBC Life Sciences reports on patent-pending, nutritional supplement

RBC Life Sciences, Inc., a provider of proprietary nutritional supplements and wound care/pain management products, announced today the debut of NeuroBright(TM), a patent-pending, nutritional supplement that improved test subjects' learning and memory skills by 50 percent during a recent laboratory trial.

20 Aug 2009

Steroid hormones found to affect gene activity

Intermittent signaling by steroid hormones can affect the way genes are expressed in rodents, according to research by scientists at the University of Bristol and the National Cancer Institute (NCI), USA. This work has major implications for understanding how steroids work and opens novel avenues for new therapies.

19 Aug 2009

Depression causes reduced function in the reward center of brain

Clinically depressed individuals are less capable of finding pleasure in activities they previously enjoyed, a recent study has proven. Research featured in the August 26 issue of the NeuroReport shows reduced brain function in the reward center of the brain in depressed individuals, when compared to healthy subjects.

19 Aug 2009

Brain's motor and perception regions disconnected in tone-deaf people

Nerve fibers that link perception and motor regions of the brain are disconnected in tone-deaf people, according to new research in the August 19 issue of The Journal of Neuroscience. Experts estimate that at least 10 percent of the population may be tone deaf - unable to sing in tune. The new finding identifies a particular brain circuit that appears to be absent in these individuals.

19 Aug 2009

Transcept Pharmaceuticals' agreement with Purdue Pharmaceutical Products may lead to staff reduction

Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT) today announced plans to reduce operating expenses by eliminating certain staff positions following its recently announced License and Collaboration Agreement with Purdue Pharmaceutical Products to commercialize Intermezzo((R) )(zolpidem tartrate sublingual tablet) in the United States.

19 Aug 2009

Algos Therapeutics changes name to Algos Preclinical Services

Following a shift in its business model from developing proprietary pain therapy products to pure contract research, Algos Therapeutics has changed its name to Algos Preclinical Services. The company's new tagline, "Expertise in pain. Legendary service. Definitive results. For better quality of life." reinforces its repositioning as the go-to-CRO (Contract Research Organization) for drug discovery and product development.

19 Aug 2009

American Asthma Foundation awards $750,000 to Dr.Charles Zuker

Dr. Charles Zuker, a renowned expert on the nerves that determine taste and smell, has been awarded $750,000 by the American Asthma Foundation (AAF). Dr. Zuker will apply his expertise to asthma by defining the nerves that contract the airways during an asthma attack in order to reduce the severity of these episodes.

19 Aug 2009

Neurofeedback 'brain training' helps surgeons improve skills

A team of researchers have found that trainee eye surgeons can significantly improve their surgical skills by regulating their own brainwave activity, using a process called neurofeedback.

18 Aug 2009

Smoking increases risk for brain shrinkage in multiple sclerosis

People who smoke and have multiple sclerosis (MS) may be at increased risk of brain shrinkage and increased brain lesions related to the disease, according to a study published in the August 18, 2009, print issue of NeurologyÂ®, the medical journal of the American Academy of Neurology. Smoking has already been linked to an increased risk of developing MS.

18 Aug 2009

Running and addiction

Although exercise is good for your health, extreme exercise may be physically addicting. Rats given a drug that produces withdrawal in heroin addicts went into withdrawal after running excessively in exercise wheels, according to new research. Rats that ran the hardest had the most severe withdrawal symptoms.

17 Aug 2009

FDA approves Extavia for multiple sclerosis

The US Food and Drug Administration (FDA) has approved Extavia(R) (interferon beta-1b), the first in a new planned portfolio of multiple sclerosis (MS) medicines from Novartis to help patients manage this devastating disease.

17 Aug 2009

New target for Alzheimer's disease

For close to a decade, pharmaceutical researchers have been in hot pursuit of compounds to activate a key nicotine receptor that plays a role in cognitive processes. Triggering it, they hope, might prevent or even reverse the devastation wrought by Alzheimer’s disease.

16 Aug 2009

Human brain distinctly separates living and non-living objects for processing

For unknown reasons, the human brain distinctly separates the handling of images of living things from images of non-living things, processing each image type in a different area of the brain. For years, many scientists have assumed the brain segregated visual information in this manner to optimize processing the images themselves, but new research shows that even in people who have been blind since birth the brain still separates the concepts of living and non-living objects.

13 Aug 2009

Promising new treatment target for Kennedy's disease

New research with transgenic mice reveals that a therapy directed at the muscle significantly improves disease symptoms of a genetic disorder characterized by destruction of the neurons that control movement. The study, published by Cell Press in the August 13th issue of the journal Neuron, highlights a promising new treatment for this currently incurable and nontreatable neurodegenerative disorder.

12 Aug 2009

Children with newly diagnosed epilepsy at risk for cognitive problems

Children who have normal IQs before they experience a first seizure may also have problems with language, memory, learning and other cognitive skills, according to a study published in the August 12, 2009, online issue of Neurology, the medical journal of the American Academy of Neurology.

12 Aug 2009

Decreased cravings for pleasure may be at root of a core symptom of major depressive disorder

Decreased motivation to seek and experience pleasurable experiences, known as anhedonia, is a primary symptom of major depressive disorder. Anhedonia is less responsive to many antidepressants and often persists after other symptoms of depression subside. However, understanding the different components of anhedonia - the desire to obtain something pleasurable versus experiencing pleasure - has been difficult for researchers to determine in humans.

12 Aug 2009

MRI used as early warning system for Alzheimer's disease and dementia

When we absorb new information, the human brain reshapes itself to store this newfound knowledge. But where exactly is the new knowledge kept, and how does that capacity to adapt reflect our risk for Alzheimer's disease and other forms of senile dementia later in our lives?

12 Aug 2009

Forest Labs and Astrazeneca to co-develop and commercialize ceftaroline

Forest Laboratories (NYSE:FRX) and AstraZeneca (NYSE:AZN) announced today they have entered into a definitive collaboration agreement to co-develop and commercialize ceftaroline in all markets outside the United States, Canada and Japan.

12 Aug 2009

New biomarkers for Alzheimer's disease

A combination of proteins in the cerebrospinal fluid can reliably identify which patients with early symptoms of dementia will subsequently develop full-blown Alzheimer's disease, a research team at the University of Gothenburg, Sweden, has found in a major international study. The results were published in this week's edition of the Journal of the American Medical Association (JAMA).

12 Aug 2009

New scientific 'edugame' develops and accelerates learning abilities for students, adults, seniors

Stephane Bergeron, M.D., CEO of Brain Center America (BCA), today announced the launch of NeuroActive LEARNING, a new scientific edugame that develops and accelerates learning abilities, for anyone 11 years of age and older, including high-school and college students, adults and seniors. The doctor-developed computer program hits the market Aug. 11.

12 Aug 2009